Indivior Pharmaceuticals, Inc. INDV 深 滬
等待開盤 08-10 09:30:00 美东时间
38.82
+0.150
+0.39%
華盛通- 最 高38.91
- 今 開38.83
- 成交量 168.70万股
- 最 低 38.08
- 昨 收 38.67
- 總市值 45.81亿
- 52周最高 42.81
- 市盈率 靜 23.66
- 換手率 1.43%
- 52周最低 22.22
- 委 比 77.12%
- 總股本 1.18亿
- 歷史最高 42.81
- 量 比 0.38
- 振 幅 2.15%
- 歷史最低 7.33
- 每 手 1
- 風險率 5.66%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
财报速睇 | Indivior Pharmaceuticals, Inc. 2026财年Q2营收3.43亿美元，同比增长13.6%；归母净利润1.22亿美元，同比增长577.8%
华盛资讯8月4日讯，Indivior Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收3.43亿美元，同比增长13.6%，归母净利润1.22亿美元，同比增长577.8%。
08-04 05:36
财报速睇 | Indivior Pharmaceuticals, Inc. 2026财年Q2营收3.43亿美元，同比增长13.6%；归母净利润1.22亿美元，同比增长577.8%
华盛资讯8月4日讯，Indivior Pharmaceuticals, Inc.公布2026财年Q2业绩，公司Q2营收3.43亿美元，同比增长13.6%，归母净利润1.22亿美元，同比增长577.8%。
08-04 04:02
Indivior Pharmaceuticals Raises FY2026 Sales Guidance from $1.215B-$1.285B to $1.295B-$1.365B vs $1.245B Est
Indivior Pharmaceuticals (NASDAQ:INDV) raises FY2026 sales outlook from $1.215 billion-$1.285 billion to $1.295 billion-$1.365 billion vs $1.245 billion estimate.
08-03 18:45
Supernus Pharmaceuticals To Merge With Indivior Pharmaceuticals; SUPN Stockholders Will Receive 1.5401 Shares Of INDV Per SUPN Share; Indivior Stockholders Will Receive One-Time Special Cash Dividend Of $1B Immediately Prior To Closing; Expected To Generate $125M In Annual Cost Synergies
Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) and Indivior Pharmaceuticals, Inc. (NASDAQ:INDV) today announced that they have entered into a definitive agreement to combine in a tax-free all-stock merger of equals transaction to create a leading diversified, central nervous system (CNS) biopharmaceut...
08-03 18:35
美股夜盘 | Bloom Energy涨8.37%，Intuitive Machines涨5.47%
Bloom Energy涨8.37%；Intuitive Machines涨5.47%；万国数据涨3.23%
07-01 15:01
美股夜盘 | Bloom Energy涨7.92%，Intuitive Machines涨6.03%
Bloom Energy涨7.92%；Intuitive Machines涨6.03%；Voyager Technologies涨3.57%
07-01 13:01
Barclays Initiates Coverage On Indivior Pharmaceuticals with Overweight Rating, Announces Price Target of $46
Barclays analyst Glen Santangelo initiates coverage on Indivior Pharmaceuticals (NASDAQ:INDV) with a Overweight rating and announces Price Target of $46.
06-18 20:49
Shares of pharmaceutical companies are trading higher as investors rotate out of chips stocks and move into non-tech industries.
Shares of pharmaceutical companies are trading higher as investors rotate out o...
06-05 02:13
Indivior Pharma Announces Findings From Two New Real-World Evidence Studies Show Adherence To Extended-Release Buprenorphine Is Associated With Lower Relapse Risk And Reduced Healthcare Utilization
Compared to patients adherent to monthly injectable buprenorphine, patients on other MOUD (adherent and non-adherent) were 3.5 to 8.1x more likely to return to opioid use.In a separate study, patients receiving monthly
05-20 21:03
